Bridging the gaps in Liquid Biopsies:

Challenges and Innovations in Early Cancer

by Eman Muhammad Babar

Abstract

As medicine advances, novel methods are standing at the forefront of traditional methods which are rapidly leading the evolution of healthcare as well as pushing its boundaries. This study explores the challenges and innovations. Cancer which has no definite cure requires innovation; in the process of research emerges liquid biopsies. Liquid biopsies are a minimally invasive molecular characterization of detecting cancer, by identifying CTCs, ctDNA, and cancer-related biomarkers released by tumors that circulate in the bloodstream. Analyzing these biomarkers enables liquid biopsies to identify signs of early metastasis or to spot minute amounts of residual cancer cells preventing a relapse after treatment. This transforms healthcare practices by diagnosing cancer early, which facilitates doctors to recognize any breakthroughs of new mutations that could be resistant to treatments and to identify how the cancer evolves. Comparatively, liquid biopsies bring forth a plethora of advancements by lowering the risk of complications generally observed in surgical tissue biopsies. These transformative innovations and implementation of methods have been observed, yet addressing the challenges is crucial as it limits their clinical effectiveness and development. Along with the high costs, liquid biopsies may not be able to detect early stages of cancer or DNA in trace amounts that are released in cases of tumors, leading to false negatives or positives; other conditions could produce similar signals. While the guidelines are still being under development the method is sufficient for cancers that shed ctDNA or CTCs into the bloodstream. This method holds the potential for enhancement and increase its incorporation into standard clinical practice for cancer diagnosis and treatment.

Keywords: Liquid biopsies, Biomarkers, CTCs, ctDNA, Metastasis, Early Cancer Detection

Bridging the gaps in Liquid Biopsies:

Challenges and Innovations in Early Cancer

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Many cancers can be cured if detected early and treated effectively. As traditional methods advance, methods that are non-invasive and more effective are needed for the development of early cancer detection. Alternative methods such as liquid biopsies have been under analysis to be implemented into early cancer detection.

Liquid biopsy compared to the traditional surgical biopsy allows the doctors to uncover a range of information about a tumor through a simple blood sample typically 5-10 mL, considering it to be a minimally invasive procedure. The shedding of small fragments of DNA into the bloodstream for tumors as they grow. Circulating Tumor DNA and Circulating tumor cells that circulate the bloodstream breaking off from the primary tumor are located to be analyzed and isolated from the blood. Exosomes are released by the small vesicles from tumors and RNA carries the tumor-specific information. Liquid biopsy analyzes these biomarkers to identify early cancer detection, it has a significantly advanced method compared to the traditional methods.

Recent advancements in liquid biopsy consist of research and implementation on expanding its applicability across various cancer types instead of a few targeted ones, as well as improving detection sensitivity and integrating this method to detect cancer early to monitor and prevent it.

Challenges and Innovations in Liquid Biopsies

Under scientific scrutiny, liquid biopsies have arising limitations that must be recognized and ameliorated. For advanced methods to be implemented in healthcare, they need to be under observation and refined into a reliable procedure for the patients. Despite its potential to expand and replace traditional methods, this study acknowledges the challenges faced while implementing liquid biopsies for early cancer detection:

The first drawback of liquid biopsies is their inability to identify cancer in its early stages, which results from the tumor's inability to shed, which causes missed diagnoses. False-negative results can occur when cancer hasn't spread since there may not be enough tumor cells or circulating tumor DNA (ctDNA) to detect it. This occurs under the assumption that some biomarkers, such as ctDNA, may also exist in illnesses, infections, or inflammation that are not malignant. Because of this, liquid biopsies can detect cancer even when there isn't a tumor. Furthermore, certain cancer types do not undergo necrosis and are more localized; those cancer types are unable to release biomarkers at detectable levels.

To fully comprehend the nature of the tumor detailed information is required. Liquid biopsies can simply provide molecular data, they are not able to provide the timor’s histopathology, location, and size unlike tissue biopsies, which makes liquid biopsies unreliable compared to the traditional method.

Liquid biopsies obtain ctDNA that are often fragmented, the DNA sequences are broken into small pieces due to processes like apoptosis or necrosis. This makes it difficult to interpret the full spectrum of genetic alterations or the fragmentation to reconstruct a complete genetic profile of the tumor, potentially leading to inaccurate and incomplete outcomes.

Advanced methods require protocols and guidelines to be universally established and implemented. The evolving nature of liquid biopsy requires protocols for sample collection and interpretation of results that might vary between labs and biomarker analysis. Lack of these protocols and guidelines can result in inconsistent results and challenges in validating the technique across different clinical settings.

Conclusively, all these differences and limitations that occur due to the implementation of a new approach to such complex mutations require a thorough analysis and evaluation to expand its effectiveness in healthcare systems. For accurate diagnosis and assessments, this is essential and could be incorporated into clinical practices for early cancer detection. While there are drawbacks, there are different approaches and techniques to allow for the technology to advance into being successfully integrated.

Bridging the Gaps in Liquid Biopsy Development

Throughout the years of research and evaluations, with technology advancing, recent advancements are improving and enhancing the use of liquid biopsy with alternatives that can help reduce the limitations and integrate liquid biopsy into clinical practice for monitoring, early detection, and treatment personalizations.

Next-generation sequencing (NGS) has recently been developed and has significantly improved the use of liquid biopsies. NGS allows the detection of minute amounts of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs). In cases where the tumor is at an early stage and the amount of biomarkers that are shed into the bloodstream from the tumor NGS makes it possible to be detected. This enables early detection of cancer and identifying tumors with conventional imaging techniques.

Researchers have developed multiplex plans that detect a wide range of biomarkers, ctDNA, CTCs, exosomes, and RNA signatures, it also improves the ability to monitor cancer progression and diagnostic accuracy. This provides more detailed insights into the patient’s metastatic behavior and tumor heterogeneity.

To potentially identify a chance of relapse earlier and to trace any amounts of tumor DNA that have remained in a patient's body ctDNA analysis to detect minimal residual disease (MRD) allows that to take place, this increases the use of liquid biopsies as its being increasingly being used to detect MRD after surgeries or therapy.

Liquid biopsies are being used to track the evolution of the tumors during their treatment. It helps identify the resistance mutations and predict the therapeutic responses. This new approach has been expanded to include liquid biopsy testing for targeted therapies, like non-small cell lung cancer (NSCLC) and melanoma. This helps clinicians make timely adjustments to therapy allowing real-time monitoring of tumors during treatment, potentially improving patient outcomes.

Clinical guidelines are evolving for liquid biopsy, especially in cancers, mostly lung and colorectal cancer, this enables monitoring treatment response and detecting mutations such as EGFR mutations. Improving clinical decision-making and facilitates the standardization of liquid biopsy as part of the routine care for cancer patients.

With traditional tissue biopsies, the risks associated with it are greater, and the less invasive nature of liquid biopsy reduces these risks. Using plasma or serum from blood samples has improved ease and is a noninvasive procedure, technologies like microfluidics which studies the behavior of fluids through micro-channels, and digital PCR testing allow rapid amplification of a specific segment of DNA that enhances the precision and reliability of sample analysis.

The recent integration of AI and machine learning algorithms can be used to analyze liquid biopsy data. These technologies help in detecting patterns in large datasets that can be missed by traditional methods of analyzing liquid biopsy. This improves the accuracy of cancer detection and prognosis prediction. AI revolutionizes cancer diagnosis and allows personalized insights into a patient's data, guiding treatment decisions.

Recently, liquid biopsies are being used and explored for use in cancers that usually are difficult to biopsy traditionally, like pancreatic, ovarian, and brain cancers, where the tumors are not easily accessible or where the procedures carry high risk. This offers new hope for the early detection of cancer by broadening the scope of implementing liquid biopsy for cancers that are challenging to treat.

These advancements allow liquid biopsies to change their specificity, sensitivity, and applicability across a range of cancers. This has the potential to revolutionize the way cancer is monitored and treated. As liquid biopsies undergo research, they could simultaneously advance the evolution of early cancer detection offering a minimally invasive and highly personalized approach to dealing with cancer. While there are still aspects of liquid biopsy to be resolved, there are resolutions that bridge the gaps in liquid biopsies.

References

2023. "Liquid biopsy in cancer: current status, challenges, and future perspectives" - Nature, Signal Transduction and Targeted Therapy.

n.d. Challenges and achievements of liquid biopsy technologies employed in early breast cancer. Accessed December 21, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC7670097/.

n.d. The Advantages and Limitations of Liquid Biopsies. https://www.labce.com/spg1629022_the_advantages_and_limitations_of_liquid_biopsies.aspx?srsltid=AfmBOopxPD34A0ZdAyQfv2uVRSLgpXRGrW5Ywu1_z5ivvNK2ePtllsir.

n.d. Liquid biopsy in cancer: current status, challenges, and prospects. https://www.nature.com/articles/s41392-024-02021-w#:~:text=The%20emergence%20of%20liquid%20biopsy,invasive%2C%20quickly%20and%20so%20on.

n.d. Recent Advances in Liquid Biopsy of Brain Cancers. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.720270/full.

n.d. Liquid biopsy in cancer: current status, challenges, and prospects - Nature.

n.d. "Artificial intelligence in liquid biopsy for cancer detection and monitoring" by Y. Wang et al., Nature Reviews Clinical Oncology, 2021.

“Cancer.” 2022. World Health Organization (WHO). https://www.who.int/news-room/fact-sheets/detail/cancer.

“The liquid biopsy.” n.d. The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring. https://pmc.ncbi.nlm.nih.gov/articles/PMC10591039/.

Nicolazzo, Chiara. n.d. “Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy.” PubMed Central. Accessed December 21, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10850354/.

“Recent advances in liquid biopsy technologies for cancer biomarker detection.” n.d. https://pubs.rsc.org/en/content/articlelanding/2022/sd/d2sd00010e?utm_source=chatgpt.com.

“What is a liquid biopsy?” n.d. Roche. Accessed December 21, 2024. https://www.roche.com/stories/liquid-biopsy-in-oncology.